Paragon Bioservices
Latest round
- Series A
Last raised
- Oct 2014
Total raised
- $13M
Investors
- 2
About Paragon Bioservices
Paragon Bioservices, Inc.Paragon Bioservices, Inc. was founded in 1990 in Baltimore, US, and operates as a subsidiary of Catalent, Inc.2 billion, finalized in May 2019.Catalent, through its acquisition of Paragon Bioservices, offers a comprehensive suite of services primarily focused on the development and manufacturing of biologics, particularly gene therapies and viral vectors. Their core product offerings include extensive expertise in the development of adeno-associated virus (AAV) vectors, which serve as delivery vehicles for gene therapies. Catalent's capabilities encompass biomanufacturing, drug product fill/finish services, and analytical testing, all designed to support clinical and commercial stages of biologic products. Their customer base includes biopharmaceutical companies ranging from startups to established enterprises, primarily in North America and Europe, seeking to accelerate the development of innovative therapies.Catalent generates revenue through a diversified transactional structure that includes partnerships and B2B contracts with biopharmaceutical clients. Typically, revenue is derived from service agreements encompassing a range of activities such as process development, manufacturing, and fill/finish services, tailored to the specific needs of each client. These agreements often involve milestone payments tied to the progress of product development and regulatory approval phases. Pricing structures vary based on the complexity and scale of services, with flagship products such as their AAV vector manufacturing services being central to their revenue model.Catalent plans to leverage the resources from its acquisition of Paragon Bioservices to enhance its product offerings and expand geographically. The firm aims to increase its capabilities in the development of gene therapies and viral vectors.2 billion is intended to bolster its production capacity and innovation in biologics. Catalent is targeting expansion into new markets in Europe and Asia by the end of 2021, aligning with the growing demand for advanced biologics and gene therapy solutions.
Who invested in Paragon Bioservices
2 investors across 1 round
See all investors in Paragon Bioservices
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Funding rounds
Series A
Oct 28, 2014
Amount
$13M
Investors
Questions about Paragon Bioservices
Who invested in Paragon Bioservices?
Paragon Bioservices has 2 investors on record across 1 venture round. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Paragon Bioservices raised?
Paragon Bioservices has raised 1 venture round. Sign up free to see how much each round raised and the total.
When did Paragon Bioservices last raise money?
Paragon Bioservices's most recent round on record is a Series A, in Oct 2014.
What does Paragon Bioservices do?
Paragon Bioservices is a pharmaceuticals company.
Where is Paragon Bioservices headquartered?
Paragon Bioservices is headquartered in Baltimore, US.
Which VCs invest in companies like Paragon Bioservices?
Among active investors with capital left to deploy, Andreessen Horowitz, Founders Fund, Accel and Thrive Capital back pharmaceuticals companies at Paragon Bioservices's stage. Their profiles are linked below.
VCs backing pharmaceuticals startups at Series A
Raising like Paragon Bioservices? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.